Ines Matos
Principal Scientist Roche
Ines G. Matos is a Principal Scientist at the Roche Innovation Center Zurich, specializing in early oncology drug discovery. She leads interdisciplinary project teams with expertise across diverse modalities, including a strong focus on ADCs. A key part of her role involves driving external innovation by evaluating new therapeutic opportunities. As a preclinical discovery scientist, she is highly experienced in assessing non-clinical data packages—from in vitro/in vivo studies to safety profiles—for promising ADCs, and identifying promising drug candidates that can be impactful cancer therapies.
Seminars
As the ADC landscape becomes busier and more crowded around validated Topo1 and MMAE payloads, the need for differentiated mechanisms is vital to ensure future conjugates can overcome anticipated resistance and deliver patient benefit
Join this workshop session to navigate the different avenues of novel payload development, assessing the emerging performance of cytotoxic, non-cytotoxic and dual payload approaches to discuss and debate the next payload wave to replace topoisomerase inhibitors
Workshop highlights include:
- Discussing the crucial need for novel ADC payloads in the face of crowded clinical landscapes and future patient resistance mechanisms
- Weighing up risk level against novelty of mechanism when approaching novel payload development: What linker payloads are showing the most promise so far?
- Evaluating the opportunity for dual payload ADCs and combination therapies to combat patient resistance
